U.S. FDA Approves CARVYKTI™ (ciltacabtagene autoleucel), Janssen's First Cell Therapy, a BCMA-Directed CAR-T Immunotherapy for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma

/PRNewswire/ -- The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the U.S. Food and Drug Administration (FDA) has approved CARVYKTI™...

Related Keywords

China ,United States ,American ,Obrian Kenney ,Peter Lebowitz ,Hemophagocytic Lymphohistiocytosis ,Ciltacabtagene Autoleucel ,Sundar Jagannath ,Jessica Moore ,Caroline Pavis ,Mathai Mammen ,Janssen Biotech Inc ,Tisch Cancer Institute ,Drug Administration ,Janssen Research Development ,Janssen Pharmaceutical Companies ,Janssen Pharmaceutical Companies Of Johnson ,None Of Janssen Biotech Inc ,American Society Of Hematology ,Exchange Commission ,Icahn School Of Medicine At Mount Sinai ,Companies Of Johnson ,European Medicines Agency ,Johnson ,American Cancer Society ,Legend Biotech United States Inc ,Legend Biotech United States ,Confidence Interval ,Risk Evaluation ,Mitigation Strategy ,Safety Information ,Boxed Warning ,Cytokine Release Syndrome ,Global Therapeutic Area Head ,Janssen Research ,Multiple Myeloma ,Medical Oncology ,Icahn School ,Mount Sinai ,Legend Biotech ,Executive Vice President ,American Society ,Janssen Biotech ,Therapy Designation ,Breakthrough Therapy Designation ,Orphan Drug Designation ,European Commission ,Release Syndrome ,Effector Cell Associated Neurotoxicity Syndrome ,Macrophage Activation Syndrome ,Nerve Palsies ,Recurrent Cytopenias ,Igg Hypersensitivity Reactions ,Use Machines ,Prescribing Information ,Pharmaceutical Companies ,Infectious Diseases ,Private Securities Litigation Reform Act ,Annual Report ,Note Regarding Forward Looking ,Quarterly Reports ,Accessed February ,Results From ,B Cell Maturation Antigen ,Patients With ,Refractory Multiple ,Annual Meeting ,Statistics About Multiple Myeloma ,The Janssen Pharmaceutical Companies Of Johnson Amp ,